FDA Approves Bayer’s Nubeqa for Wider Use in Prostate Cancer Subtype.
In combination with docetaxel, the U.S. Food and Drug Administration (FDA) has approved Bayer’s Nubeqa for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC).Nubeqa (darolutamide) was previously approved for the treatment of non-metastatic castration-resistant prostate ... [Read]
The Phase 1b study by Aligos Therapeutics to assess its Class II Capsid Assembly modulator, ALG-000184, started with a 12-week dosing cohort.
The clinical-stage biopharmaceutical company Aligos Therapeutics, Inc. (Nasdaq:ALGS), which focuses on creating novel treatments for unmet medical needs in viral and liver diseases, announced today that enrollment in a 12-week dosing cohort of HBeAg-positive chronic ... [Read]
FDA provides a positive pre-IND response to Alzamend Neuro for AL001.
Alzamend Neuro, Inc. (Nasdaq:ALZN) is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”), and post-traumatic stress disorder (“PTSD”), announced today ... [Read]
Cronos Group and Geocann Work Together to Use VESIsorb® Delivery Technology for Quicker Absorption
In collaboration with Geocann, Cronos Group Inc. is happy to announce the release of the first of what is anticipated to be several products that will make use of the cutting-edge VESIsorb® delivery system. Faster ... [Read]
Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA
Amryt (Nasdaq: AMYT), a multinational, commercial-stage biopharmaceutical company with a focus on acquiring, developing, and commercializing novel treatments for rare diseases, today announced its intention to submit a Formal Dispute Resolution Request (FDRR) for its ... [Read]
Eton Pharmaceuticals Sells Hospital Supplies to Dr. Reddy’s for up to $50M
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today declared that it had agreed to sell its hospital goods to Dr. Reddy’s Laboratories SA, a ... [Read]
Evaxion Biotech Broadens EVX-03 DNA Vaccine Project Into Non-Small Cell Lung Cancer.
Evaxion Biotech A/S (NASDAQ: EVAX) a clinical-stage biotechnology company focused on the creation of AI-driven immunotherapies, announced today that it has chosen EVX-03 as the product candidate within its DNA technology platform to target a ... [Read]
Optimi Health Requests for Authorization to Manufacture MDMA, Other Synthetic Psychedelics
Optimi Health Corp, a native Canadian business that creates natural, scalable, and affordable mushroom formulations for transformational human experiences, has made a health request to Canada for an amendment to the Controlled Substances Dealer’s Licence. ... [Read]
Energy Hemp Biotechnology Ltd. Appointed by Charlotte’s Web for Distribution in the Greater China Region
Jacques Tortoroli, Charlotte’s Web’s Chief Executive Officer, said, “We have been developing this opportunity with Energy Hemp for some time and are proud to announce this new partnership to launch into Greater China.” Charlotte’s Web ... [Read]
Braxia Scientific Expands Network of Ketamine and Psilocybin Specialists.
Braxia CEO Dr. Roger McIntyre said, “Today’s announcement is the first of what we intend to be a series of growth developments and acquisitions to our clinical network.” Braxia Scientific Corp. is a medical research ... [Read]